Paz-Ares ESMO 2016
Lux Lung 7
Overall Survival by mutation type
0
6
12
18
24
30
36
42
48
93
91
88
88
82
74
68
63
61
54
50
41
35
24
20
9
1
0
93
88
86
82
79
72
66
57
52
46
39
36
29
28
17
5
0
0
67
65
65
60
57
51
43
41
33
27
24
20
15
12
10
3
1
0
66
65
62
60
54
47
39
33
28
25
23
20
19
16
10
2
0
0
0
0
Estimated OS probability
Estimated OS probability
0
6
12
18
24
30
36
42
48
Time (months)
Time (months)
Afatinib
Gefitinib
No. at risk:
Afatinib
Gefitinib
No. at risk:
1.0
0.8
0.6
0.4
0.2
1.0
0.8
0.6
0.4
0.2
Afatinib
N=93
Gefitinib
N=93
Median, mo
30.7 26.4
HR (95% CI)
p-value
0.83 (0.58–1.17)
0.2841
Del 19
Afatinib
N=67
Gefitinib
N=66
Median, mo
25.0 21.2
HR (95% CI)
p-value
0.91 (0.62–1.36)
0.6585
L858R
